MI-3 is primarily used in research focused on targeting specific protein-protein interactions, particularly between menin and mixed lineage leukemia (MLL) fusion proteins. It is studied for its potential in treating acute leukemias, especially those driven by MLL rearrangements, which are often associated with poor prognosis. By inhibiting the menin-MLL interaction, MI-3 disrupts the oncogenic pathways that promote leukemia cell proliferation and survival. This makes it a promising candidate for developing targeted therapies in hematologic malignancies. Additionally, MI-3 is utilized in preclinical studies to better understand the molecular mechanisms underlying menin-dependent cancers and to evaluate the efficacy of menin inhibitors in combination with other anticancer agents.